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Background: Clinical characterization of motion in patients with Parkinson disease (PD) is challenging: symptom progression,
suitability of medication, and level of independence in the home environment can vary across time and patients. Appointments
at the neurological outpatient clinic provide a limited understanding of the overall situation. In order to follow up these variations,
longer-term measurements performed outside of the clinic setting could help optimize and personalize therapies. Several wearable
sensors have been used to estimate the severity of symptoms in PD; however, longitudinal recordings, even for a short duration
of a few days, are rare. Home recordings have the potential benefit of providing a more thorough and objective follow-up of the
disease while providing more information about the possible need to change medications or consider invasive treatments.
Objective: The primary objective of this study is to collect a dataset for developing methods to detect PD-related symptoms
that are visible in walking patterns at home. The movement data are collected continuously and remotely at home during the
normal lives of patients with PD as well as controls. The secondary objective is to use the dataset to study whether the registered
medication intakes can be identified from the collected movement data by looking for and analyzing short-term changes in walking
patterns.
Methods: This paper described the protocol for an observational case-control study that measures activity using three different
devices: (1) a smartphone with a built-in accelerometer, gyroscope, and phone orientation sensor, (2) a Movesense smart sensor
to measure movement data from the wrist, and (3) a Forciot smart insole to measure the forces applied on the feet. The measurements
are first collected during the appointment at the clinic conducted by a trained clinical physiotherapist. Subsequently, the subjects
wear the smartphone at home for 3 consecutive days. Wrist and insole sensors are not used in the home recordings.
Results: Data collection began in March 2018. Subject recruitment and data collection will continue in spring 2019. The intended
sample size was 150 subjects. In 2018, we collected a sample of 103 subjects, 66 of whom were diagnosed with PD.
Conclusions: This study aims to produce an extensive movement-sensor dataset recorded from patients with PD in various
phases of the disease as well as from a group of control subjects for effective and impactful comparison studies. The study also
aims to develop data analysis methods to monitor PD symptoms and the effects of medication intake during normal life and
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outside of the clinic setting. Further applications of these methods may include using them as tools for health care professionals
to monitor PD remotely and applying them to other movement disorders.
Trial Registration: ClinicalTrials.gov NCT03366558; https://clinicaltrials.gov/ct2/show/NCT03366558 
International Registered Report Identifier (IRRID): DERR1-10.2196/12808
(JMIR Res Protoc 2019;8(3):e12808)  doi: 10.2196/12808
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Introduction
Parkinson disease (PD) is a progressive and degenerative
disorder of the central nervous system, affecting both the
physical and psychological health of the patient [1]. James
Parkinson described the physical symptoms of the disease in
1817 as “the shaking palsy” [2], naming rest tremor as one of
the distinguishing features. Rest tremor, rigidity, and
bradykinesia (ie, the slowness of movement) are considered the
main motor indicators of PD [1]. In addition to these motor
symptoms, PD may affect the cognitive ability by causing
dementia and indirectly affecting the mental health by increasing
the risk of depression [1]. In recent years, nonmotor
manifestations of PD have been given more recognition, and
updates in the diagnostic criteria have been made to systematize
the diagnostic process [3].
Motor symptoms are caused by the accumulation of
alpha-synuclein protein in the central nervous system and the
loss of dopaminergic neurons, thus reducing limb movement
and control of the body. The symptoms usually start
asymmetrically as a rest tremor or rigidity in one of the upper
or lower limbs. The symptoms degrade the physical condition
and decrease movement, thus affecting the quality of life. [1]
In clinical practice, the symptoms are evaluated on a visual
basis, but several studies have used wearable sensors and
smartphones to identify the symptoms such as tremor [4-6],
freezing of gait [7-8], and dyskinesia [9-10]. Although the
symptoms can be identified visually, wearable sensors provide
the possibility to monitor the patient remotely and collect more
quantifiable data of the progression of symptoms. To our
knowledge, there are two medical devices for monitoring of
PD: The Personal KinetiGraph system for measuring
bradykinesia, dyskinesia, tremor, and sleep [11-12] and the
Kinesia Technology [13] for measuring tremor, dyskinesia, and
mobility.
The diagnosis of PD is based on an interview, a physical
examination, and an evaluation of the medical history of the
patient by a physician. The consulting neurologist confirms the
neuropathological indicators of the disease and rules out other
conditions with similar manifestations using imaging and
laboratory tests. If clinically needed, the symptoms are
suppressed by prescribing dopaminergic drugs after the PD
diagnosis is confirmed. When the disease progresses, a variety
of medications and different therapy techniques must be used
to help with the symptoms. [14] Patients visit their neurologists
to adjust their medications, while control visits are organized
constantly throughout the progression of the disease.
There are three symptomatic states in PD that depend on the
level of medication. (1) The “Off” state implies that the
dopamine level is too low in the central nervous system, thus
increasing the cardinal features of PD: tremor, slowness, and
rigidity. (2) The “On” state is the optimal dopamine level in the
central nervous system, which implies very little or no sign of
the disease, depending on how much the disease has progressed.
(3) The overmedicated state is a hyperkinetic state in which the
dopamine level is too high. This causes dyskinetic movements,
fast walking and movements, and dystonic changes in the
posture or limbs. [15] The effect of the medication is fast, but
it may also wear off fast, before taking the next dose.
There are several challenges associated with diagnosing and
monitoring PD with the current clinical practice. Clinical
heterogeneity complicates the diagnosis because the patient
may have a variety of symptoms of varying intensity and timing
[14]. The symptoms present during the clinic appointment may
not reveal all of the issues that are present at home, and the
ability to cope independently may vary substantially between
the On and Off states. On the other hand, prescribing the right
dose of medication and scheduling doses to prevent Off states
is challenging. Sudden fluctuation of On/Off states may be
recognizable with wearable sensors that have automated
algorithms [16]. To handle this challenge of recognizing
fluctuations, remote monitoring at home would help health care
professionals prescribe medication, and with complicated PD,
it would help decide the optimal timeframe for secondary,
invasive PD treatments such as deep brain stimulators or
intraduodenal levodopa infusions.
In addition to the previous studies on identifying motor
symptoms and current medical devices, we aim to build an
affordable remote monitoring system using patients’ own
devices, allowing long-term monitoring with minimal effort to
the patient. The system is developed based on the findings from
the data-collection process and future studies. This study is an
observational case-control study that aims to collect a dataset
from patients with PD and healthy controls by measuring their
movements during daily life, using a smartphone and wearable
sensors. The primary objective of the data analysis is to
determine if PD-related motor symptoms can be detected and
classified based on inertial signals recorded at home. Motor
symptoms could also be used to determine whether the subject
is in an early or progressed stage of the disease. The secondary
objective is to distinguish changes in motor symptoms after a
dose of the medication is taken. These changes should be visible
with patients having distinct “On” and “Off” states in their
motor symptoms. Home monitoring of patients with PD and
automated data analysis could help health care professionals
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validate the level of motor symptoms and monitor the effects
of medication. The long-term goal is to develop an affordable
and easy-to-use solution for remote home monitoring of PD.
Methods
Inclusion and Exclusion Criteria
The inclusion criterion for the study group is the diagnosis of
PD according to the International Classification of Diseases-10
code G20 [17]. All subjects were recruited from the Satakunta
region in Finland. The common inclusion criteria for both the
study and control groups were minimum age of 30 years, ability
to walk at least 20 steps unassisted (use of assistive devices
such as a walking stick were allowed), and no deep brain
stimulation therapy during the study. In addition, the subject
must not have been diagnosed with diseases causing symptoms
similar to PD, such as multiple system atrophy, progressive
supranuclear palsy, corticobasal degeneration, Lewy body
dementia, or parkinsonism induced by a dopamine antagonist
drug (ie, an antipsychotic drug such as metoclopramide). In
addition, all subjects were required to speak and write fluent
Finnish.
The control subjects are not specifically age matched to the
patients, since both groups are recruited and studied at the same
time and we aim to maximize the number of participants in both
groups. However, recruiting control subjects from the family
members of patients, for example, partners, balances the age
distribution. Medical background information is collected from
both groups to record conditions that affect the walking skills.
Study Design
A study sample of 150 subjects will be recruited, of which 100
will be patients with PD and 50 will be healthy controls.
Approximately 50 of the patients with PD will be in an early
stage of the disease and the other 50 will be in a progressed
stage of the disease. This classification is based on the modified
Hoehn and Yahr Staging of PD [18], where patients with a score
of 0-2 are considered to be in the early or mild stage of the
disease, and patients with scores of 2.5-5 are considered to be
in the progressed or more severe stage of the disease. Both the
study and control groups go through the same measurement
protocol, including a clinic visit with questionnaires and tests
and a home measurement for 3 consecutive days. The home
measurement period aims to record data showing short-term
changes in walking patterns related to the On/Off state changes
or wearing-off effect of medication. In addition, the period can
be used to evaluate the subjects’ physical activity at home.
Figure 1 presents the study protocol.
When a subject has been recruited, the study protocol begins
with an appointment with a physiotherapist at Satakunta Central
Hospital in Pori, Finland, or another appropriate location in the
Satakunta region. First, the physiotherapist interviews the subject
and collects his/her background information, diagnoses, medical
histories, and current medications. Thereafter, the subject and
physiotherapist fill in the structured questionnaires together.
All the questionnaires were selected from official Finnish
translations. The validated Finnish versions of the tests used in
this study include the Alcohol Use Inquiry, C version [19]; the
Depression Scale [20] to determine depressive symptoms; the
Mini-Mental Status Examination [21] to determine the level of
global cognition; and the Unified Parkinson’s Disease Rating
Scale (UPDRS) [22] to determine the severity of PD symptoms.
The UPDRS examination includes both interviews and physical
examinations performed by the physiotherapist. The subject
also performs a 20-step walking test while wearing all the
sensors in addition to the physical examination performed during
the UPDRS test [23]. During this 20-step walking test, the
subject walks straight at his/her own pace for 20 steps in a
hallway. The physiotherapist counts the steps silently and asks
the subject to stop walking after 20 steps. The subjects do not
count their steps, since rhythmic aids may help patients with
PD to walk more normally. The timing of the previous PD
medication is recorded for reference.
After the appointment at the clinic, the subjects wear the sensors
for 3 consecutive days during their daily lives. The sensors are
not worn during sleep or while showering or swimming. During
these 3 days, the subject registers the intake time of all PD
medications in a smartphone app as well as in a paper diary
format. This manual recording was added, since the patients
were having problems using the medication registration button
despite the simple user interface. The double registration process
ensures that medication intake is recorded as accurately as
possible. The subjects also record other events, such as falls
and other adverse effects, and feedback in the diary.
Figure 1. The study protocol consists of six phases, all of which are completed by both patients and control subjects. MMSE: Mini-Mental Status
Examination; UPDRS: Unified Parkinson's Disease Rating Scale.
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This study recruits subjects through two routes. In the first route,
patients are recruited from Satakunta Central Hospital. These
subjects are outpatients who visited the hospital due to PD in
the past 5 years. The study physiotherapist sends an
informational letter to the subjects and follows up by phone 1
week later. The physiotherapist introduces the study and asks
if the patient is willing to participate. If the patient is willing to
participate, the physiotherapist sets up an appointment at
Satakunta Central Hospital.
In the second route, the physiotherapist and the responsible
investigator (neurologist) visit local PD communities in the
Satakunta region and give lectures on the study and its
intentions. After the presentation, the patients and their family
members (partners) have the opportunity to sign up for the study
in either the study or control groups. If many volunteers sign
up, the physiotherapist may organize appointments at clinics in
these locations to minimize travel costs and effort from the
patients.
If the study cohort is incomplete after these recruitment
processes, an advertisement is published in the local newspaper,
as well as the Satakunta Central Hospital newsfeed, to inform
potential subjects about the study and ask for participation.
Hospital staff and the research consortium were recruited as the
control group, in addition to the family members of the study
subjects.
Since the study is solely based on recruiting volunteers, there
is a risk of some bias in the study cohort, both amongst patients
and controls. It is difficult to recruit subjects with a lot of health
problems or with very severe PD symptoms. For example,
subjects with depression or severe cognitive issues may not
want to participate, even if their physical condition is appropriate
for the study. However, our aim is to include all the volunteers
fulfilling the inclusion criteria into the study and consider the
properties causing bias in the analysis phase.
Roles of the Research Staff in Data Collection
The physiotherapist involved in this study is a trained clinical
physiotherapist who works with neurological patients in the
hospital. The physiotherapist is responsible for contacting the
subjects, scheduling appointments, conducting measurements,
instructing the subjects to use the devices, and cleaning the
measurement devices after each use. The subjects may contact
the physiotherapist as well as the researchers to provide more
information and ask for help when using the devices. All the
devices are provided by the research group. Therefore, the
subjects do not need their own smartphones or other devices in
the study. The study smartphone is only used for data collection
and not for any personal use.
A researcher at Tampere University in Tampere, Finland, assists
in conducting the measurement protocol at the hospital and
monitors the operation of the data-collection system. The
data-collection system consists of sensors that measure the data
and a smartphone that buffers and sends data through an internet
connection to a server located at Tampere University, where
the researcher inspects the data on a personal computer. The
researcher assists the physiotherapist with the devices, if any
problems occur.
Ethical Approval and Trial Registration
This study is conducted according to the Ethical Principles for
Medical Research Involving Human Subjects, as stated in the
2013 revised version of the 1964 World Medical
Association Declaration of Helsinki. All information collected
by Tampere University is coded and does not contain identifying
information. The identifying data are held appropriately in a
locked storage facility at Satakunta Hospital District, and only
the study physiotherapist and the responsible investigator are
allowed to view them.
A favorable statement was obtained for the study protocol from
the Ethics Committee of the Hospital District of Southwest
Finland in Turku [24] on October 24, 2017 (ETMK
101/18012017). Minor changes to the study protocol were made
based on tests of the measurement protocol with 10 pilot
subjects. These changes were approved by the ethics committee
in April 2018. For example, the UPDRS test was extended to
the healthy control group. The changes to the measurement
protocol are further discussed in the Results section of this paper.
In addition to the ethical committee statement, the National
Supervisory Authority for Welfare and Health (Valvira) in
Helsinki, Finland, approved the study in April 2018
(identification number 394-2018).
The KÄVELI study is registered at ClinicalTrials.gov
(NCT03366558) [25].
Sensors Used in the Study
Data are collected using three types of sensors: built-in inertial
sensors in a mobile phone (Nokia 6, HMD Global Ltd, Finland)
provided by the study, a wrist-worn wearable device measuring
a gyroscope signal (Suunto Movesense, Suunto Ltd, Finland
[26]), and a smart insole measuring ground reaction forces in
the feet (Forciot smart insole, Forciot Ltd, Finland [27]). The
primary measurement device is the smartphone, since it is used
both in the clinic and at home for all subjects. The other two
devices are used mainly in the clinic, but the Forciot insole is
also tested in home settings with a few subjects who were
comfortable using the additional device.
The subjects also registered their PD medication intake in a
smartphone app set to the home screen of the phone. However,
to ensure that the medications are correctly registered, the
subjects are asked to write their PD medication intake in a
manual diary format as well. Figure 2 presents the sensors used
in this study.
The smartphone contains built-in sensors for acceleration,
angular velocity, and orientation, which are used to measure
the movements of the phone while it is carried by the subject,
thus providing information about their movement dynamics.
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Figure 2. Sensors used in the study: Movesense smart sensor (upper left corner), Forciot smart insole (upper right corner), and Nokia 6 smartphone
(lower left corner).
While the subject is wearing the device on the waist, the
acceleration describes the changes in velocity and orientation
of the subject in the linear direction, and cyclic movements such
as walking are visible as cyclic changes in the acceleration. The
gyroscope describes the rate of changes in orientation in relation
to the center of the phone. The orientation signal describes the
orientation of the phone in three dimensions, in which the phone
orientation can be checked. This signal helps to check if the
subject accidentally wears the phone in a different position than
instructed.
These sensors are available in most smartphones and are used,
for example, in mobile games, compasses, and step counters.
The smartphone is located in a waist-worn small bag in front
of the stomach. Use of the bag ensures that the device can be
worn regardless of the type of clothing; thus, no pockets are
needed. The placement was set in front, so that it would not
disturb the subject when sitting or lying down. The phone is
oriented horizontally with the positive X-axis facing upward
and the positive Z-axis facing forward. Figure 3 presents the
phone’s orientation and location.
The data recorded by the sensors are further used to classify the
subject’s walking patterns. We selected the Android 8–based
Nokia 6 smartphone for data collection because of its ability to
effectively disable all power-management settings. This is an
important feature to successfully collect long-term data. The
instantaneous sampling frequency of the sensors varies between
50 Hz and 100 Hz due to implementation of the data-collection
framework. All the signals measured with the smartphone are
resampled to 100 Hz during signal processing. The measurement
ranges for the accelerometer and the gyroscope are ±16 g and
±34.9 radians/second, respectively, and their resolutions are 14
bit and 16 bit, respectively; in addition, their internal
peak-to-peak noise level ranges were found to be roughly ±1
mg and ±0.005 radians/second, respectively.
Suunto Movesense, manufactured by Suunto Oy [26], is a heart
rate– and movement-monitoring sensor worn on the wrist in
this study during the physical examination of the UPDRS. The
device communicates with the mobile phone using Bluetooth
low energy, and the sampling frequency of Movesense is 52
Hz. The measurement range is ±34.9 radians/second. The data
provided by this sensor can be used, for example, to measure
the rest tremor and detect attenuated arm swing during walking,
which is a typical symptom in PD.
The Forciot smart insole, manufactured by Forciot Oy [27], is
a pressure-sensing insole prototype that includes 23 sensing
elements distributed, so that they cover the whole area of the
sole with a sampling frequency of 50 Hz. The smart insole also
calculates the applied total force by integrating the data of the
individual sensing elements. One insole is used during the
UPDRS examination at the clinic appointments. Two subjects
also used a pair of insoles during the home measurements. Thus,
the insole provides information on the walking pattern and
pressure distribution in the feet.
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Figure 3. The orientation of the smartphone when worn on the waist. The X-axis measures vertical movement, the Y-axis measures horizontal movement
in the lateral direction, and the Z-axis measures movement in the posterior-anterior direction. The phone is worn in a bag on the waist and inserted
correctly on the stomach side with the screen out and the right side up.
Data Collection and Management
This study introduces a novel perspective on the mobile
microservice architecture in a data-transfer system [28]. In this
system, all sensors and wearable devices act as independent
services with their own architecture. However, with a common
interface between the server and the services, data can be
collected simultaneously and asynchronously. In fact, the entire
front-end, back-end concept is flipped because the smartphone
acts as a server behind the simple user interface, and the personal
computer acts as a client who is requesting information
according to the data-collection frequency set by the personal
computer user. Figure 4 presents an overview of the
data-collection system.
The smartphone worn by the subject collects information from
all the sensors and stores it temporarily. The size of the buffer
on the phone is adequate for storing data of up to 1 hour, but
after that time, the system will start to overwrite the data. The
wearable devices are paired with the smartphone in the
beginning of a recording, but after a momentary loss of
connection, they will reconnect automatically. The personal
computer for data collection acts as a client and requests
information from the smartphone via an internet connection by
using the smartphone’s internet protocol address. In this study,
the frequency for requesting the signals is 5 minutes. The client
receives the information via the internet connection and stores
the data in text files. Several subjects can be measured
simultaneously because each subject only requires one
smartphone and the wearable devices. The personal computer
for data collection can also save several data-collection streams
simultaneously within the Linux operating system.
There are two approaches to securing information during data
transfer: (1) encrypting the information before sending it through
an unsecured connection and (2) building a secure connection
between a smartphone and a router that cannot be accessed by
any internet protocol addresses other than the ones used by the
data-collection smartphones and the client’s personal computer.
The former approach was tested at the beginning of the study,
and the data were collected successfully in an encrypted form.
However, a secure connection improves efficiency during data
management and signal processing, because the files are ready
to use immediately after data collection. The second solution
was also implemented and tested during the project in
cooperation with a local telecommunications company.
However, no identifying information is transmitted through the
internet connection. The subject identification and smartphone
are accurately linked manually before analyzing the data. This
implementation will be more thoroughly discussed in future
publications related to the data-collection system.
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Figure 4. An overview of the structure of the data-collection system. The system consists of three independent systems: (1) a Linux system, (2) an
android system acting as a temporary server, and (3) a Bluetooth low-energy system consisting of independent wearable devices.
This database will be granulized and compressed into a format
that can be used in further analyses, including structuring the
information, developing the metadata, and ensuring anonymity
of the data. For example, rather than knowing the exact date of
the measurement, only the time of the day and season will be
recorded when analyzing walking habits.
Data Verification
Data verification requires confirming that the measured signals
have the appropriate quality to accurately distinguish walking
segments from other movements and to use the signals for
further analysis. The possible issues faced during home or clinic
measurements are also recorded and analyzed, including, for
example, usability issues with the technology as reported by
the participants or network issues leading to the loss of data.
These analyses would confirm that there is an appropriate
amount of high-quality data that is usable in machine learning
applications. If any such problems are identified in the
measurement setup, they will be fixed to ensure the quality of
the data.
The collected signals are checked both visually and statistically
to assess whether they contain the necessary information for
the classification of different types of movements. A minimum
sampling frequency of 50 Hz was required for the measurements
conducted with the smartphone based on the previous studies
presenting human walking under 10 Hz [29] and hand tremors
in PD under 20 Hz [30]. The measurements will be discarded
if they are below a 50-Hz sampling frequency. Suunto
Movesense and Forciot use their own sampling frequencies of
52 Hz and 50 Hz, respectively.
Information is collected on how many files were successfully
recorded during a 3-day measurement. Successful measurements
are defined as those that are recorded and transferred correctly
and have the appropriate sampling frequency. This information
is used to monitor how well the measurement system functions
when the subject is responsible for merely charging the
smartphone and restarting it if the power runs out. The
performance analysis includes battery life, possible network
issues, and usability issues. These properties are studied and
used in further development of the measurement system.
Data Analysis
Methods for data analysis are developed and structured based
on a data-analysis pipeline. This pipeline includes data
preprocessing, walking detection, calculation of features related
to changes in walking, and feeding the features into a
machine-learning system to classify the symptoms and subjects.
The classification results and the performance of the classifier
are then analyzed. The main features of data analysis include
the identification of patients with PD from healthy subjects
based on sensor data and prediction of UPDRS scores from the
sensor data. The long-term target is to build an automated
classification system that could support home monitoring by
using machine learning methods. All the data analysis will be
done in Python 3 (Python Software Foundation, Wilmington,
DE) and MATLAB (The MathWorks, Inc, Natick, MA).
We will be using a data-driven approach to analyze and compare
a large number of features calculated from the signals of the
different sensors. However, we will consider possibilities to
combine the information of different sensors to define such
features or parameters that are likely relevant to PD, for
example, the amount of arm swing during walking. The
incompleteness of the data set (wrist and insole sensors not
included in all the recordings), however, limits the use of
parameters requiring combining sensor information. This will
be discussed in future publications on the data analysis.
The preprocessing phase includes the signal-processing steps
that are required before the signals can be used in further data
analysis. The signals are resampled to obtain a constant sampling
frequency; simultaneously measured signals are aligned to have
the same starting and ending time; and, if necessary, the signals
can be filtered with a basic low- or high-pass filters.
An accurate walking-detection algorithm and careful selection
of machine-learning features are important when developing
the data-analysis pipeline. Activity-detection algorithms have
already been developed by other research groups, for example,
based on the mean amplitude deviation [31-32], which is more
thoroughly defined in another previous study [33]. An algorithm
based on the existing literature will be developed and
implemented during this study. The walking-detection algorithm
may extract either walking segments or individual steps. When
recognizing the walking patterns from home data, we may use
the 20-step walking tests as a personal reference of the subject’s
walking style. Walking detection from the 20-step tests is rather
easy, since the signals only contain walking or standing.
Walking detection will be thoroughly analyzed and discussed
in future publications considering the analysis of data from
home measurements.
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The selection of features is also important when building a
machine-learning system for health care use. The features should
describe real physiological changes in the walking patterns; for
example, if the patient is in the On state with good balance in
the medication, his/her walking is classified as better than the
same patient without the medication (Off state). Although On
and Off states are not specifically defined in this study, we aim
to recognize the differences before and after taking the
medication. Features can be selected with a statistical approach,
for example, by applying the minimum Redundancy Maximum
Relevance algorithm [34] or the theoretical understanding of
PD to choose features related to the physiological changes in
the patients. Features may include both statistical features of
the signals such as mean, median, or SD, or they can be defined
from the physiology and be based on traditional features used
in gait analysis, such as step length or speed.
The subjective UPDRS classification performed by the
physiotherapist is used to test the classification of the subjects
from the 20-step walking tests. The UPDRS score can be used
as the true label of the subject’s current state, and the walking
tests are classified into several groups identifying the severity
of motor symptoms in walking. In home measurements, the
UPDRS score defined at the clinic may be used to test whether
the classification result before taking the PD medication differs
from that soon after taking the medication. Alternatively,
unsupervised learning methods such as clustering approaches
may be used to study whether there are differences in the feature
values before and after taking the medication.
The classification phase includes applying different machine
learning classifiers to study the most feasible method for
classifying the symptoms and changes in symptoms related to
medication intakes. For example, a support vector machine [35]
and random forest [36] will be used to classify walking patterns.
Classification performance is evaluated by a confusion matrix
and the metrics related to it including accuracy, sensitivity,
specificity, and the receiver operating characteristic curve. Other
measures may be added to evaluate the performance more
thoroughly.
The data analysis aims to develop methods to answer the
following hypotheses: (1) Can we distinguish patients with PD
from healthy controls by using wearable sensors and machine
learning classifiers? (2) Can we assess the severity of symptoms
before and after medication intake? These key hypotheses may
be further specified or expanded in further analyses. These
methods, combined with the novel data-collection method, can
be further developed into a home-monitoring system for health
care professionals and neurological patients.
Results
Data collection began in March 2018 by testing the measurement
protocol with 10 subjects. These subjects will be included in
the final study sample. Minor improvements were made to the
measurement protocol based on the first subject’s recordings
in the clinic and in-home measurements. The changes included
(1) the double registration of medications, as discussed in the
Methods section of this paper, and (2) the decision to conduct
the UPDRS questionnaires and tests with the control subjects,
even though they were not expected to have PD symptoms.
All three measurement devices were planned to be used in the
home measurements, but due to the technical requirements of
Suunto Movesense [26] and Forciot [27] insole, they were not
implemented in the protocol for data collection at home. Forciot
[27] insoles were tested with subjects for 1 day prior to the
3-day home measurement. Two subjects were tested during the
study. This is because the insoles are operated by a battery,
which only has a lifetime of 24 hours. In addition, Suunto
Movesense [26] was connected using a Bluetooth connection,
and the connection was not sufficiently stable to be used at
home. Therefore, the device was only used in the clinic
measurements.
After the pilot study, the capacity of simultaneous studies
increased from 3 to 10. Most of the subjects were recruited from
the PD community visits where there was a lot of interest to
participate in the study. A secure internet connection was set
up for data transfer by building a private mobile network for
the research project in cooperation with a local
telecommunications company. This network was tested and
implemented in August 2018. After the update, encryption of
the measurement data was not needed because the network was
only accessible by devices in the study. By the end of December
2018, we collected data from a total of 103 subjects, 66 of whom
are patients with PD and 37 are control subjects. Subject
recruitment and data collection will be continued in the spring
of 2019.
Discussion
This paper describes the research protocol for a PD-monitoring
study involving the use of smartphones and wearable sensors,
also known as the KÄVELI project. This study aims to gather
a dataset of 150 subjects to develop methods for monitoring
PD-related motor symptoms in daily life. The user-friendly
measurement setup is enabled by a data-collection system that
consists of several microservices that automatically collect
movement information when a subject wears the measurement
device and registers their PD medication intake manually and
through a smartphone app. There has been an increasing trend
in studies toward home monitoring of PD with, for example,
smartphones [7,23,37-39] and other wearable sensors
[4,8,37,40-42]. In addition, several research groups have
developed algorithms for recognizing various types of
movements such as walking, running, and climbing stairs
[31,32,43-45]. Based on the literature, there is a potential for
monitoring PD with wearable solutions and machine-learning
principles. These principles are applied in order to recognize
the descriptive features of walking segments as well as to
determine what sensors are required to achieve accurate
recognition of the symptoms and evaluate their severity. The
selection of correct features is important for linking the results
to real physiological changes that are evident in the subjects’
walking.
Some mobile health platforms have been proposed to monitor
PD patients during preset tests, such as PD Dr [6] and
PD_manager [46], both of which have been tested on a relatively
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small set of patients with PD. HopkinsHD [47] is collecting
data from free-living people and has been tested on a set of 226
subjects, both control subjects and patients with PD. These
platforms have resulted in indications that home monitoring of
PD patients is feasible. Our aim is to provide a platform that is
suitable for long-term monitoring and uses the patients’ own
smartphones or very affordable wearable sensors.
Most of the previous studies concentrating on the recognition
of PD symptoms with wearable sensors have been conducted
with relatively small datasets (10-50 subjects in total), which
are feasible for proposing new methods in data collection or
analysis, but not enough to validate the system with a larger
variety of subjects. Some studies, however, have recruited more
subjects [23,37,47]; these studies have collected larger datasets
of several hundred subjects. Larger studies will be needed to
validate systems before implementing them into a commercial
product. The dataset collected in the KÄVELI project will be
valuable in the investigation of PD motor symptoms in a
quantitative manner, whereas the present clinical monitoring
of PD is based on the subjective information provided by the
patient and clinical observations by a neurologist or
physiotherapist [25]. Despite the opportunities and new
innovations presented by wearable sensors and machine
learning, home monitoring has several practical challenges that
must be evaluated and solved before they can become a common
part of clinical routines. First, independent use of technological
devices may create difficulties among the elderly, and
acceptance of technology takes time and special effort in
usability. Second, even if the technology itself is not new to the
patients, severe motor symptoms and Off states combined with
cognitive and memory disorders may complicate the registration
of medication intakes or other tasks given to the patient [48].
Finally, even though home monitoring allows for measurements
to take place in real-life situations that provide a more extensive
view of symptoms, ensuring adherence to the measurement
protocol is impossible outside of the clinical environment. For
example, subjects can be reminded to register their medication
intake, but they may forget to register it anyway, or the
placement of the device might be changed unexpectedly.
The KÄVELI project’s measurement protocol aims to minimize
these challenges by developing a user-friendly interface for the
smartphone that registers medication intake and by providing
written and spoken instructions for the use of all devices
included in the study. The level of instruction also aligns with
the subject’s confidence with technology. This is assessed by
a question in the background interview: “How confident are
you in using a smartphone?” which is also recorded in the study
material. In addition, the physiotherapist can be reached by
phone for further instruction if any challenges occur during the
measurement period.
Despite the simple user interface of the smartphone (only one
visible button for the medication recording), some subjects have
had issues using the smartphone. Therefore, medications were
also recorded in a paper format, which led to extra work for the
subjects. This limitation, as well as any adverse effects or
usability issues, will be recorded and considered in the
development of the measurement system.
One potential limitation to the study is the recruitment of control
subjects. It may be difficult to collect a dataset with a variety
of mobility skills and still match the age group of patients with
PD. We have recruited control subjects from among the patients’
family members, but this might also be considered a limitation.
These challenges must be addressed accordingly when carrying
out the study.
In conclusion, this study will provide quantitative information
on PD motor symptoms and their statistical properties. The
collected dataset will be used to develop algorithms and create
tools for remote monitoring of PD progression by physicians
and to assist with adjusting the medication.
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